Kikuchi YS, et al. - To assess the effectiveness and tolerability of aripiprazole for the treatment of psychotic symptoms in subjects with dementia with Lewy bodies (DLB), authors examined 11 candidates in this 10-week, open-label study design. They initiated aripiprazole at a low dose (3 or 6 mg/day) and titrated to higher doses at 2-week intervals or more rapidly, as required. They noticed an improvement in the mean Neuropsychiatric Inventory (NPI) and the Brief Psychiatric Rating Scale (BPRS) scores until the fourth week. Later, the improvements slowed and continued without significant reduction. A decrease in the median Simpson–Angus Scale (SAS) scores at the endpoint vs the baseline was also recorded. In treating psychotic symptoms in patients with DLB, aripiprazole may be efficacious and well tolerated.